Literature DB >> 12653833

Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies.

L A Trouw1, M A Seelen, J M G J Duijs, H Benediktsson, C Van Kooten, M R Daha.   

Abstract

Anti-C1q autoantibodies are present in the serum of patients with different autoimmune diseases such as systemic lupus erythematosus (SLE). The occurrence of these autoantibodies correlates with renal involvement. In the present study we examined whether injection of rabbit antimouse C1q antibodies in mice leads to deposition in kidneys. Injection of healthy mice with a single dose of rabbit IgG antimouse C1q antibodies resulted in deposition of both C1q and IgG anti-C1q in glomeruli. The pattern of deposition observed in the glomeruli of mice injected with antimouse C1q antibodies both at 24 h and 2 weeks was both glomerular basement membrane (GBM)-associated and mesangial. Injection of control IgG did not have a detectable effect on circulating C1q levels, and no deposition of either C1q or rabbit IgG was seen at 24 h. The deposition of rabbit antimouse C1q and C1q in glomeruli resulted in complement activation, as assessed by C3 deposition, and influx of leucocytes associated with albuminuria in some, but not all mice. In none of the control mice was albuminuria observed. This report is the first to show that anti-C1q antibodies deposit in the healthy glomerulus together with autologous C1q. This deposition is stable for at least 2 weeks, causes complement activation, leucocyte influx and can lead to mild albuminuria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653833      PMCID: PMC1808680          DOI: 10.1046/j.1365-2249.2003.02108.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

Review 1.  Complement. Second of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-12       Impact factor: 91.245

Review 2.  Complement. First of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 3.  Autoantibodies to complement components.

Authors:  L A Trouw; A Roos; M R Daha
Journal:  Mol Immunol       Date:  2001-08       Impact factor: 4.407

4.  Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients.

Authors:  M Trendelenburg; J Marfurt; I Gerber; A Tyndall; J A Schifferli
Journal:  Arthritis Rheum       Date:  1999-01

5.  The effect of high salt concentration on detection of serum immune complexes and autoantibodies to C1q in patients with systemic lupus erythematosus.

Authors:  Junko Kohro-Kawata; Mark H Wener; Mart Mannik
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

6.  Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis.

Authors:  Feng Lin; Steven N Emancipator; David J Salant; M Edward Medof
Journal:  Lab Invest       Date:  2002-05       Impact factor: 5.662

7.  DNA levels in circulating immune complexes decrease at severe SLE flares-correlation with complement component C1q.

Authors:  A Bengtsson; R Nezlin; Y Shoenfeld; G Sturfelt
Journal:  J Autoimmun       Date:  1999-08       Impact factor: 7.094

8.  Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis.

Authors:  H Sogabe; M Nangaku; Y Ishibashi; T Wada; T Fujita; X Sun; T Miwa; M P Madaio; W C Song
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

9.  Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus.

Authors:  U Antes; H P Heinz; M Loos
Journal:  Arthritis Rheum       Date:  1988-04

Review 10.  Complement and systemic lupus erythematosus.

Authors:  Mark J Walport
Journal:  Arthritis Res       Date:  2002-05-09
View more
  19 in total

1.  Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis.

Authors:  Zhu Chen; Guo-Sheng Wang; Gui-Hong Wang; Xiang-Pei Li
Journal:  Clin Rheumatol       Date:  2012-06-14       Impact factor: 2.980

Review 2.  Antibodies against C1q in patients with systemic lupus erythematosus.

Authors:  Marten Trendelenburg
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

3.  Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice.

Authors:  Chunyan He; Xuehong Lu; Zhaowei Yan; Man Wu; Shujun Liu; Yongli Yu; Ping Luo
Journal:  Rheumatol Int       Date:  2010-12-03       Impact factor: 2.631

4.  Anti-C1q autoantibodies in murine lupus nephritis.

Authors:  L A Trouw; M A Seelen; R Visseren; J M G J Duijs; H Benediktsson; E de Heer; A Roos; C van Kooten; M R Daha
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

5.  Activation-induced deaminase heterozygous MRL/lpr mice are delayed in the production of high-affinity pathogenic antibodies and in the development of lupus nephritis.

Authors:  Chuancang Jiang; Ming Lang Zhao; Marilyn Diaz
Journal:  Immunology       Date:  2008-06-20       Impact factor: 7.397

6.  Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus.

Authors:  V Michael Holers
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

7.  Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes.

Authors:  Leendert A Trouw; Tom W L Groeneveld; Marc A Seelen; Jacques M G J Duijs; Ingeborg M Bajema; Frans A Prins; Uday Kishore; David J Salant; J Sjef Verbeek; Cees van Kooten; Mohamed R Daha
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

8.  Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.

Authors:  N Marto; M L Bertolaccini; E Calabuig; G R V Hughes; M A Khamashta
Journal:  Ann Rheum Dis       Date:  2004-07-29       Impact factor: 19.103

9.  Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice.

Authors:  Chuancang Jiang; Julie Foley; Natasha Clayton; Grace Kissling; Micheal Jokinen; Ronald Herbert; Marilyn Diaz
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

10.  Autoantibodies against mannose-binding lectin in systemic lupus erythematosus.

Authors:  M A Seelen; L A Trouw; J W A van der Hoorn; F C Fallaux-van den Houten; T W J Huizinga; M R Daha; A Roos
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.